CompanyMBXNasdaqCarmel, IN

MBX Biosciences

MBX Biosciences develops precision peptide therapies for endocrine and metabolic disorders.

SEC EDGAR ClinicalTrials.gov optimize-study.com

424B4Sep 28Latest SEC filing

Aug 27Latest story

August 2026

MBX Biosciences doses first patient in Phase 3 trial of canvuparatide for hypoparathyroidism

Aug 27Clinical readoutcanvuparatide MBX Biosciences

MBX Biosciences reports Q2 2026 results, canvuparatide Phase 3 recruiting

Aug 6Clinical readoutcanvuparatide MBX Biosciences

July 2026

MBX Biosciences registers Phase 3 trial of canvuparatide for hypoparathyroidism

Jul 13Trial updatecanvuparatide MBX Biosciences

MBX Biosciences names Steven Hoerter CEO as Kent Hawryluk departs

Jul 13PeopleMBX Biosciences